Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 18/20 | 0.47 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19726804 | 0.82 | ERN1 (0.52) | ERN1BRD4 | |
| SCHEMBL19231554 | 0.79 | ERN1 (0.49) | ERN1BRD4 | |
| SCHEMBL19726802 | 0.79 | ERN1 (0.49) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL16225552 | 0.77 | ERN1 (0.56) | ERN1BRD4BRD2 | |
| SCHEMBL1664331 | 0.77 | ERN1 (0.59) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL17813564 | 0.77 | BRD4 (0.66) | ERN1BRD4CREBBP | |
| SCHEMBL20578010 | 0.77 | DHFR (0.35) | ERN1BRD4 | |
| SCHEMBL19231446 | 0.76 | BRD4 (0.55) | ERN1BRD4BRD2CREBBP | |
| SCHEMBL16861736 | 0.76 | BRD4 (0.50) | BRD4BRD2CREBBP | |
| SCHEMBL16225411 | 0.75 | ERN1 (0.54) | ERN1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412669-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040063-A1 | TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | BRD3, BRD4, BRPF3 | ERN1 1624/4885BRD4 2/4885BRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.